2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Emerging Trends in Oncolytic Virus Therapy
Oncolytic virus therapy is an innovative cancer treatment that uses genetically modified viruses to selectively infect and kill cancer cells. These viruses are designed to replicate within tumor cells, causing cell lysis while sparing healthy cells. Additionally, oncolytic viruses can stimulate the immune system to recognize and attack cancer cells, providing an added therapeutic benefit. Emerging trends in oncolytic virus therapy focus on improving viral selectivity, enhancing immune responses, and combining the therapy with other cancer treatments, such as immune checkpoint inhibitors. This promising treatment has shown potential in clinical trials, with several viruses demonstrating efficacy against various types of cancer. Ongoing research aims to optimize these therapies and expand their clinical applications.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China